ABSTRACT Objective: Because altered serotonin (5-HT) function appears to persist after recovery from bulimia nervosa (RBN), we investigated the 5-HT 1A receptor, which could contribute to regulation of appetite, mood, impulse control, or the response to antidepressants. 
Introduction
Bulimia nervosa (BN) is a disorder of unknown etiology that tends to occur in adolescent and young adult women. 1 Individuals with this illness suffer from cycles of binge eating, usually followed by self-induced vomiting or other purging behaviors, as well as disturbances of mood and impulse control.
Considerable physiologic and pharmacologic data show that disturbances of serotonin (5-HT) function occur in individuals with eating disorders. 2, 3 The 5-HT 1A receptor is of interest in eating disorders because it has been implicated in the modulation 4, 5 of mood, impulse control, and appetite as well as the response to antidepressant medication. 6 Positron emission tomography (PET) and the ligand [carbonyl- 11 C]WAY100635 ([ 11 C]WAY) can be used to investigate the binding potential (BP) of this receptor. The 5-HT 1A autoreceptor is located presynaptically on 5-HT somatodendritic cell bodies in the raphe nuclei, where it functions to decrease 5-HT neurotransmission. 4 High densities of postsynaptic 5-HT 1A exist in the hippocampus, septum, amygdala, and entorhinal and frontal cortices, where they serve to mediate the effects of released 5-HT.
Despite differences in BP measurements [for a definition of BPs see consensus nomenclature for in vivo imaging for reversibly binding radioligands 7 ] and radioligands used, studies have tended to show elevated binding of the 5-HT 1A receptor 2, 3 in individuals with eating disorders, and some relationship between 5-HT 1A receptor binding and measures of harm avoidance (HA). Specifically, individuals ill with BN had elevated [ 11 C]WAY BP P , 8 previous studies from our group found 9 that women ill with anorexia nervosa (AN) had a highly significant (30-70%) increase in [ 11 C]WAY BP P , whether they were restrictive or bulimic-type AN. Finally, our group 10 found that women recovered from bulimic-type AN had a persistent 22% to 43% increase in [ 11 C]WAY BP P . While women recovered from restrictive-type AN had normal [ 11 C]WAY BP P , 10 [ 11 C]WAY BP P values were markedly elevated in some participants and were most recently found to be significantly increased in lean and recovered restricting-type AN individuals (using the radioligand [ 18 F]MPPF and BP ND ).
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This is the first study to investigate 5-HT 1A receptor binding in recovered BN (RBN) individuals who have never had AN. It is not known whether extremes of dietary intake, or other factors related to the ill state, are a cause or consequence of abnormal 5-HT function. To avoid these possible confounding effects, we studied RBN, and compared them to age-and weight-matched control women (CW). More than 50% of individuals who have BN recover (i.e., their binge and purge symptoms disappear). Nonetheless, these individuals often continue to have persistent dysphoric mood, obsessional thoughts, and body image concerns that are modest compared to the ill state. 12 Such behavioral symptoms are present in childhood, before the onset of BN. Thus, they may reflect traits that contribute to a vulnerability to develop BN. It should be emphasized that other 5-HT system abnormalities in recovered BN are profound, including approximately a 50% elevation of cerebrospinal fluid hydroxyindoleacetic acid (CSF 5-HIAA) (the major metabolite of brain 5-HT), 13 reduced 5-HT 2A receptor binding in frontal regions, 14 altered mood response to 5-HT agents, 13, 15 and evidence of reduced 5-HT transporter function in RBN 16 and ILL BN. 17 Together, these findings support the hypothesis that a substantial dysregulation of serotonergic neuronal circuits occurs in BN.
Method

Participants
We studied 13 RBN and 21 healthy CW recruited through local advertisements. None of the BN subjects had a history of AN. To be considered ''recovered,'' individuals had to have met the following criteria for the previous year: (1) maintain a weight above 90% of average body weight; (2) have regular menstrual cycles; (3) have not binged, purged, restricted food intake or exercised excessively; (4) not used psychoactive medications such as antidepressants; (5) no current alcohol or drug abuse/dependence. CW had no history of any psychiatric, serious medical or neurological illness. This study was conducted according to local institutional review board regulations and all subjects gave written informed consent. The PET imaging was performed during the first 10 days of the follicular phase of the menstrual cycle for all participants as the potential effect of different phases of the menstrual cycle on 5-HT 1A binding in some regions, e.g. the dorsal raphe, cannot be fully excluded. 18 Methods are described in detail elsewhere. 10 Mean BP P values for 21 CW were previously reported. 9, 10 Data on the 13 RBN participants have not been reported previously.
Behavioral Assessments
All participants underwent a face-to-face interview with a psychiatrist using the Structured Clinical Interview for DSM-IV Axis I Disorders 19 to assess lifetime prevalence of Axis I psychiatric disorders. Current psychopathology and personality traits (Table 1) were assessed with a battery of standardized instruments designed to characterize temperament (Temperament and Character  Inventory, TCI) , 20 mood (Beck Depression Inventory, BDI), 21 anxiety (Spielberger State-Trait Anxiety Inventory, STAI), 22 and impulse self-control (Barratt Impulsiveness Scale, BIS). 23 The Novelty Seeking, Harm Avoidance, and
Self-Transcendence scales were used from the TCI. The value for one RBN who had a BIS self-control score over two standard deviations (SDs) below the mean was removed from the correlations.
Image Acquisition
Magnetic resonance (MR) imaging and PET imaging were performed as previously described for arterialbased dynamic imaging of 
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A metabolite corrected input function was determined, as previously described. 24 The temporal stability of the outcome measures was examined in the subset of participants for which a full 90 min emission data set was available. High correlations were observed between the 60-and 90-min datasets for both the Logan cerebellar distribution volume (V ND ) and regional Logan BP P measures, respectively (CW: r 5 .95-.99; RBN: r 5 .962.99). The bias across regions of interest (ROIs) between the two measures was similar for CW (9.4% 6 4.1%) and RBN participants (8.4% 6 4.2%; p 5 .71). This observation supports the validity of the results for the 60 min interval.
PET Data Processing
The ROIs were hand-drawn on the coregistered MR images and applied to the dynamic PET data to generate time-activity curves. ROIs have been described previously. 10, 24 Briefly, ROIs included the cerebellum (left and right hemispheres) as a reference region, and prefrontal, lateral orbital frontal, medial orbital frontal, parietal, mesial temporal, subgenual cingulate cortical regions, and the dorsal raphe nucleus. Because the raphe nuclei cannot be delineated on MR, this ROI was directly identified on the PET image 27 using circular fixed 6 mm radius ROIs (for all participants) placed over the area of highest radioactivity. The inferior border of the dorsal raphe nucleus was identified by the interpeduncular cistern. To reduce noise, right and left regions were combined. 25 We denote here the outcome variables using the recently issued consensus nomenclature for in vivo imaging for reversibly binding radioligands. 7 For the arterial-based kinetic analyses, regional [ 11 C]WAY distribution volume (V T ) was determined using both the Logan graphical method 28 and three-compartment model (2-tissue compartments) 26 that included a vascular volume term. A modified Logan analysis that applied generalized linear least squares smoothing to the data prior to analysis 29 was used as this method effectively reduced noiseinduced bias in the Logan V T as previously described for other PET radiotracers. 28 The Logan analysis was performed using integrated PET data intervals that were each determined over 0 2 T i min after injection, where T i ranged from 25 to 60 or 90 min, with 7 or 10 data points used for the analyses of the 60 and 90 min data sets, respectively. Our main outcome measure for this study was BP. The BP measure was determined as: BP P 5 V T 2 V ND . 26 This BP P is dependent on plasma protein binding (f P ) rather than tissue-free fraction (f ND ). 26 As a result, plasma protein binding was measured in all participants to determine the extent to which a group difference in [ 11 C]WAY BP P could be influenced by this factor. For comparison purposes, we also determined BP ND as:
It is acknowledged that [ 11 C]WAY is a radiotracer with low nondisplaceable tissue uptake and quantification of the cerebellar V ND can be problematic. Complicating factors include technical issues related to PET imaging (i.e., scatter, spillover from occipital radioactivity), low levels of receptor binding in vermis, and variable sensitivity at radiotracers (data not shown). The cerebellar white matter was not used because it did not appear to exhibit in vivo kinetics consistent with nondisplaceable uptake in receptor-rich areas.
Statistical Analysis
Standard statistical software packages (SAS Version 8.2, StatExact 4.0, and SPSS 14.0) were used for all analyses except the multivariate profile analysis described later. Comparisons between RBN and CW were made using Wilcoxon rank-sum tests. Exact p-values were computed due to the small sample sizes. Standard regression diagnostics were used to assess the sensitivity of the model to outlying and highly influential observations in the data set. Pearson correlation coefficients were also computed and exact significance levels based on Monte Carlo methods are reported. All values are expressed as mean 6 SD. We applied a Sidak correction to control for Type I errors in the analysis of group differences in ROIs for BP P and BP ND (Table 2 ). This type of correction is more appropriate than other methods (e.g., Bonferroni) when the multiple tests performed are not independent. 34 Otherwise, we assumed a p value of p \ .05 for declaring significance.
Multivariate distance matrix regression (MDMR) 35 was used to examine the extent to which similarity in 5-HT 1A receptor binding profiles was related to several predictor variables of interest. MDMR is an analytic method, which involves the construction of a dissimilarity or distance matrix that, in this case, reflects the correlation of study participants' profiles with respect to BP values over all of the brain regions sampled. Predictor variables, including age, BMI, and measures of behavior were then tested for association with variation in the BP P distance matrix using the statistical program DISTLM forward. 36 Independent variables were tested both individually and in a forward stepwise manner, with p-values computed via permutation analysis. The independent variables selected are based on the highest cumulative proportion of variance in BP P distance, explained by the inclusion of an additional variable in the regression model.
Finally, a repeated-measures ANOVA was used to explore potential group differences in radiolabeled metabolites of [ 11 C]WAY. Because sphericity tests failed, Using a Logan analysis ( Table 2 and Fig. 1 ) the RBN women showed significant elevations of postsynaptic receptor BP P , and a trend for increased autoreceptor BP P compared to CW. After a conservative adjustment for multiple comparisons, findings persisted for the subgenual cingulate, mesial temporal, and parietal regions. Group differences for the compartmental analysis were similar, but less robust ( Table 2 20 for all ROIs surveyed (Fig. 2) . These findings were the most robust for the prefrontal cortex (r 5 2.73, p 5 .0003), orbital frontal cortex (r 5 2.61, p 5 .005), and parietal cortex (r 5 2.65, p 5 .002), but also were significant for the lateral orbital frontal cortex (r 5 2.55, p 5 .01), subgenual cortex (r 5 2.49, p 5 .03), mesial temporal cortex (r 5 2.52, p 5 .02), and dorsal raphe (r 5 This is the first study to show that increased [ 11 C]WAY BP P also occurs in women recovered from BN with no history of AN. These results supplement previous evidence showing that elevated binding of the 5-HT 1A receptor occurs in individuals with eating disorders. Several interpretations are possible, which will require further testing to confirm. First, in recovered state, increased binding of the 5-HT 1A receptor may be associated specifically with RBN, whether or not they have had a history of AN. RBN have been shown to have elevated cerebrospinal fluid concentrations of hydroxyindoleacetic acid (CSF 5-HIAA) 13 and evidence of reduced 5-HT transporter function, 16 consistent with increased extracellular 5-HT concentrations. Theoretically, increased postsynaptic 5-HT 1A receptor activity could be compensatory means of counteracting increased extracellular 5-HT. 37, 38 Second, elevated 5-HT 1A receptor binding may be further exaggerated in the ill state of both AN and BN individuals, suggesting a possible trait phenomenon that is exacerbated by nutritional abnormalities.
These data may provide insight into pharmaceutical treatments for BN. Although numerous controlled trials have shown some efficacy for a variety of antidepressant medications in BN, relatively few individuals achieve abstinence on medication, as most continue to binge and purge. For example, a large-scale controlled trial of fluoxetine, which showed that a relatively high dose of 60 mg/day was superior to 20 mg/day for BN, 39 had a 1-year remission rate of only 17.7%. Many participants remained symptomatic on medication and there was a worsening on all measures of efficacy over time. This result is consistent with other clinical observations 40 that suggest limited improvement and considerable relapse with long-term antidepressant treatment in BN. An important mechanism thought to contribute to the action of SSRIs is the desensitization of the somatodendritic 5-HT 1A autoreceptor on the raphe neurons. 6 Highly elevated 5-HT 1A receptor activity in BN raises the question of whether BN individuals have difficulty in achieving SSRI-induced 5-HT 1A autoreceptor desensitization. Such a difficulty could explain the need for higher doses of fluoxetine as well as partial response to drugs. Perhaps higher doses of SSRIs or the addition of 5-HT 1A specific agents may prove useful in BN.
The RBN individuals continued to have mild to moderate levels of depressive and anxiety symptoms. However, while individuals with eating disorders tend to have elevated [
11 C]WAY BP P , reduced binding of 5-HT 1A receptor ligands has been found in most [for review see Refs. 41 and 42] , but not all studies of major depression (BP F ). 43 In addition, reduced binding of 5-HT 1A receptor ligands has been found in social phobia (BP ND ) 44 11 C]WAY BP P in CW and RBN, respectively. The instruments used to assess behavior in humans tend to assess complex phenomena that are likely to be a composite of many traits, therefore confounding the understanding of how behaviors might be associated with a 5-HT receptor. For example, HA measures anxiety and behavioral inhibition, whereas novelty seeking measures exploration and impulsivity. 20 Similarly, assessment of behavior in ani- Studies of male and female healthy controls using PET and [
11 C]WAY BP have found negative relationships in frontal, temporal, and cingulate regions with self-transcendence (BP ND ), 47 and negative (BP F ) 48 as well as positive (BP ND ) 49 correlations with aggression. In individuals with major depression, [ 11 C]WAY BP F was correlated negatively with somatic anxiety and positively with psychic anxiety in cingulate and frontal regions. 50 The BP ND measure in 5-HT 1A receptor binding studies has been associated negatively with the neuroticism facet of anxiety on the NEO 17 in healthy controls. Similar to RBN, [ 11 C]WAY BP P was associated with HA in recovered restrictive-type AN. 10 There is an extensive literature associating the serotonergic system and 5-HT 1A receptor activity with fundamental aspects of behavioral inhibition. 51 Reduced CSF 5-HIAA levels are associated with increased impulsivity and aggression in humans and non-human primates, whereas increased CSF 5-HIAA levels are related to behavioral inhibition. 52 Activation of brainstem 5-HT 1A receptors inhibits stress-induced sympathetic activity and fight-or-flight behavioral responses. 53 5-HT 1A receptors modulate impulse control through effects on catecholamine systems 54 and blunted 5-HT 1A receptor number or function is associated with increased aggression. 55 Taken together, these data raise the possibility that 5-HT 1A receptor may contribute to the emergent ability to inhibit or self-control the expression of a number of behaviors related to stimulus seeking, anxiety, aggression and impulsivity. Within the context of eating behavior, it is important to note that both AN and BN tend to restrict their eating and lose normal meal patterns 56 and show high harm avoidance, a measure of anxiety and inhibition. However, AN can maintain this inhibition continuously, whereas BN have periodic disinhibition and loss of self-control. 5-HT 1A functional activity reflects one part of a complex system of 14 or more receptors and many other components that modulate metabolism, firing rate, neuronal cascades, etc. For example, we find recovered restrictive-type and bulimictype AN have differences in 5-HTT function 57 which might explain why these subtypes have differences in impulse control or inhibition. Thus, an understanding of the complexities of 5-HT function will likely be needed to truly understand the relationship of this system to behavior.
Limitation
The interpretation of the findings in this study is complicated because of observed group differences in nonspecific factors (e.g., cerebellar V ND and plasma protein binding, 1/f P ). The receptor binding measures reflect both the concentration of available receptors (B avail ) and the dissociation constant (K D ), as well as nonspecific factors (i.e., BP P 
. Therefore, we performed a secondary examination of the data to facilitate interpretation of the BP differences.
First, the cerebellar V ND measure was greater for RBN participants than controls whether determined using a Logan analysis or two-tissue compartment model (i.e., V ND 5 K 1 /k 2 3 (1 1 k 3 /k 4 )). The greater RBN cerebellar V ND resulted more from the (K 1 /k 2 3 k 3 /k 4 ) term than the K 1 /k 2 term that were respectively, 0.42 and 0.44, as compared to the values for control participants of 0.15 and 0.38, respectively. The greater difference observed for the compartmental V ND -relative to the Logan V ND -may result, in part, from variability in the kinetic parameter estimates determined in an area of low radioactivity concentration. Despite the greater RBN V ND measures, significantly greater 5-HT 1A receptor binding was observed in multiple brain areas whether BP was determined through V ND subtraction or ratio (using Logan or compartmental analysis) and the greater RBN V ND measures would serve to minimize increases in either BP P or BP ND for the RBN group.
Second, the average f P value for CW (i.e., 0.09) was consistent with [ 11 C]WAY f P values recently reported for controls, 58, 59 while the average f P value for RBN participants (i.e., 0.14) was about 56% greater (with inversely lower protein binding of 36%) relative to CW. This f P difference was statistically significant despite large measurement variation ( 35%) for both groups. The regional V T values (Logan or compartmental analysis) for RBN participants were also significantly greater than those for CW across all regions, with the exception of the dorsal raphe. This observation could be consistent with greater radiotracer availability as a result of lower plasma protein binding in the RBN participants, but the magnitude of the V T increases (relative to CW) varied across regions (21-32%) rather than being on the order of 56% (i.e., the group difference in f P ).
Correction of the BP P measure for f P yields BP F 5 B avail /K D . A group comparison of the BP F measures yielded a reversal of the BP P difference, reflecting BP F values of CW greater than those of RBN (data not shown). This difference was not statistically significant when an individual f P correction was performed on a subject-by-subject basis, but was significant when the group f P average values were applied. Confidence in the correction was dampened by the level of variation in f P and the fact that f P values were not available for all participants. Potential associations between the f P values and use of birth control pills among participants and estradiol or BHBA levels were also examined but these results were unremarkable. Significantly lower f P has most recently been found in remitted depressed participants compared to controls, 43 as well as nonsignificantly lower f P among currently depressed participants compared to controls, 59 although the origin of these differences remain unclear. Paradoxical group differences for BP P and BP ND relative to those for BP F have been noted in other [ 11 C]WAY PET investigations of neuropsychiatric disorders, 43 particularly when BP F was determined based on the use of cerebellar white matter to approximate nondisplaceable radiotracer uptake. In this work, the cerebellar reference uptake was determined in predominantly gray matter areas (low white matter contribution) using methods that were carefully defined to minimize well-known sources of error (see Methods section).
In conclusion, the BP P binding measure showed evidence of significantly greater 5-HT 1A receptor binding in subgenual cingulate, mesial temporal and parietal cortices of participants recovered from bulimia nervosa, relative to healthy controls. This work also indicated group differences in nonspecific factors that raised concern about the direction of this group difference in 5-HT 1A receptor binding. The BP P measure is determined using standard methods with minimal ''nonspecific'' corrections. This work further highlights the importance of careful measurement and evaluation of non-specific factors in neuroreceptor binding studies including the need to verify potential plasma protein binding differences between eating disorder groups, and to address the potential nature of such f P differences in RBN.
